Hadrien has been in charge of different positions at Kurma (analyst, associate and now as principal). He has participated in a dozen investments of the Kurma Biofund II and III funds. Hadrien has actively contributed in particular to the creation of several portfolio companies such as Dynacure, Imcheck Therapeutics, Flamingo Therapeutics, Ermium Therapeutics and Corlieve Therapeutics. Hadrien holds a PharmD from the Faculty of Pharmacy, Lille, and a Master in Entrepreneurship from the ESSEC Business School.
Management team
Scientific Advisor
Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris
Board Of Directors
Scientific Advisory Board
Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris
Chief Executive Officer of the Institute for Research in Immunology and Cancer at the University of Montréal
Professor of Target and Systems Biochemistry at the Faculty of Science of the Vrije Universiteit Amsterdam
